aleniglipron
aleniglipron: developed by 1 company · 4 clinical trials tracked.
aleniglipron evidence translation
What we can confirm
4 tracked trials
What it means
What to watch
Prepared research question
How could aleniglipron → GPCR affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence6 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (3)
| Company | Phase |
|---|---|
| Structure Therapeutics Inc. (GPCR) Obesity, Overweight, or Chronic Weight Management | Phase 3 |
| Structure Therapeutics Inc. (GPCR) Type 2 diabetes mellitus (T2DM) and obesity | Phase 2 |
| Structure Therapeutics Inc. (GPCR) Obesity; Obese; Obesity, Overweight, or Chronic Weight Manag… | Phase 2 |
Clinical Trials (4)
A Long-Term Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Multiple Maintenance Doses of Oral Once Daily Aleniglipron for Chronic Weight Management in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
Primary endpoint: Percent change in body weight from Baseline
A Randomized, Double-Blind, Placebo-Controlled, Pivotal Phase 3 Study to Evaluate the Long-Term Efficacy and Safety of Multiple Maintenance Doses of Once Daily Oral Aleniglipron for Chronic Weight Management in Adults With Obesity or Overweight and a Weight-Related Comorbidity
Primary endpoint: Percent change in body weight from Baseline
A Phase 2, Randomized, Double-blind, Placebo-controlled, Study of the Safety and Tolerability of Aleniglipron in Adult Participants With Type 2 Diabetes Mellitus Living With Obesity or Overweight
Primary endpoint: Incidence, severity and relationship of AEs/SAEs
A Phase 2b, Randomized, Double-blind, Placebo-controlled, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity (Body Mass Index ≥ 30 kg/m2) or Overweight (Body Mass Index ≥ 27 kg/m2) With at Least One Weight-related Comorbidity
Primary endpoint: Percent change in body weight from Baseline to Week 36
Frequently asked questions
Who is developing aleniglipron?
aleniglipron is being developed by Structure Therapeutics Inc..
How many clinical trials involve aleniglipron?
BioSniper tracks 4 clinical trials involving aleniglipron.